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OBJECTIVES The present study investigated the effects of tumor necrosis factor (TNF)-alpha and
angiotensin II (ANG II) on cardiac remodeling and dysfunction at the early stage of acute
myocardial infarction (MI) by using a novel heterotopic cardiac transplantation–coronary
ligation model.
BACKGROUND A recent clinical study has demonstrated a possible role of monocytosis in the development
of left ventricular (LV) remodeling in patients with acute MI reperfusion.
METHODS We performed isogenic heterotopic cardiac transplantation and simultaneous coronary
ligation to produce MI in the donor heart and to evaluate the hearts of both donors and
recipients in Lewis rats.
RESULTS A significant decrease in LV fractional shortening and positive rate of rise in LV pressure and
a significant increase in LV end-diastolic dimension/body weight and LV end-diastolic
pressure were observed in the recipient hearts in the ligation group on day 7. TNF-alpha was
significantly elevated not only in the plasma but also in the recipient hearts in the ligation
group. In contrast, ANG II was significantly increased only in the infarct region of the donor
hearts, but not in the plasma. Furthermore, the recipients’ transient LV remodeling and
dysfunction were completely abolished by the intravenous administration of a TNF-alpha
antagonist.
CONCLUSIONS We developed a novel cardiac transplantation–coronary ligation model capable of inducing
MI in the absence of downstream hemodynamic effects and allowing differential quantifica-
tion of indexes of cardiac remodeling in vivo, including the local and remote effects of ANG
II and TNF-alpha on cardiac remodeling. (J Am Coll Cardiol 2003;42:173–81) © 2003 by
the American College of Cardiology Foundation
Myocardial infarction (MI) induces global changes in ven-
tricular architecture that are collectively referred to as
“post-MI remodeling” (1). A variety of peptides, including
norepinephrine, angiotensin II (ANG II), endothelin, aldo-
sterone, and tumor necrosis factor (TNF)-alpha, a pro-
inflammatory cytokine, substantially contribute to disease
progression in the failing heart (2). In this highly complex
environment after MI, it is quite difficult to differentiate the
effects of individual neurohormones and cytokines on car-
diac remodeling, even when using the conventional MI
model. Previous studies have shown that TNF-alpha is
expressed by cardiac myocytes contralateral to the infarcted
lesion, where myocardial remodeling is ongoing; such pro-
duction has been shown to play a role in an important
intrinsic myocardial stress response to injury (3). Although
clinical data have shown that circulating levels of TNF-
alpha are elevated in heart failure (HF), the exact biochem-
ical mechanisms responsible for the transition from hemo-
dynamic compensation to decompensation remain unknown
(4). A recent clinical study has demonstrated a possible role of
monocytosis in the development of left ventricular (LV)
remodeling in patients with acute MI reperfusion (5). In the
present study, to examine the effects of TNF-alpha and ANG
II on cardiac remodeling and dysfunction at the early phase of
acute MI, we performed isogenic heterotopic cardiac trans-
plantation and simultaneous coronary ligation in Lewis rats
and evaluated the donor and recipient hearts, which were
beating independent of each other.
METHODS
The study protocol was approved by the Institutional
Animal Care and Use Committee of Yamaguchi University
School of Medicine, in accordance with the guidelines of
the American Heart Association.
A total of 256 inbred male Lewis rats (175 to 225 g) were
purchased from Charles River, Inc. (Montreal, Canada).
Isogenic heterotopic cardiac transplantation was performed
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according to the method of Ono and Lindsey (6). Proximal
left anterior descending coronary artery ligation in the donor
heart was performed immediately after the transplantation
and at the same surgical intervention site (Fig. 1). Myocar-
dial ischemia was confirmed by regional cyanosis. As a sham
operation, nonligated hearts were transplanted into the
same strain of rats. The viability of the donor heart was
assessed based on the beating of the transplanted heart. To
examine the effects of the TNF-alpha receptor antagonist
(TNFR:Fc), a TNF-alpha antagonist (Amgen, Thousand
Oaks, California) that is a chimeric fusion protein consist-
ing of the extracellular domain of the Fc portion of the
immunoglobulin G1 molecule, on both recipient and donor
cardiac function, six rats in the ligation group were post-
surgically treated with a single subcutaneous injection of
TNFR:Fc at a dose of 1.5 mg/kg body weight (7). The effect
of recipient heart MI on the donor heart was not measured,
owing to high mortality.
Both donor and recipient hearts were weighed, and 5-m
serial sections stained with hematoxylin and eosin were used
for quantitative histologic analysis to determine the LV
dimension, wall thickness, and infarct size (%MI), accord-
ing to the method of Pfeffer et al. (1). The perivascular
index of the recipient heart was examined and scored from
0 to 2, using all cross sections stained with Masson’s
trichrome solution, according to the method of Matsusaka
et al. (8). The average score was calculated for each heart.
On days 7 and 21 after surgery, body weight and body
temperature were measured, and systolic blood pressure and
heart rate (HR) were obtained by the tail-cuff method. Both
recipient and donor hearts underwent echocardiographic
and hemodynamic evaluation.
Left ventricular end-diastolic dimension (LVEDD), LV
end-systolic dimension (LVESD), and fractional shortening
(%FS) were obtained by averaging three cardiac cycles using
an echocardiographic system (HP SONOS 5500; Hewlett
Packard, Palo Alto, California) with a dynamically focused
12-MHz linear-array transducer under light anesthesia with
ether. Next, LV function (intracavitary LV systolic and
diastolic pressures) in both hearts was recorded as previously
described (9).
White blood cell (WBC) counts were measured with an
auto cell counter on days 7 and 21 after surgery. To test for
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
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LVESD  left ventricular end-systolic dimension
MCP  monocyte chemoattractant protein
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Figure 1. An anatomic scheme of cardiac transplantation and simultaneous coronary artery ligation. Isogenic heterotopic cardiac transplantation was
performed by end-to-side anastomosis of the ascending aorta of the donor heart to the abdominal aorta of the recipient and donor pulmonary artery to the
recipient inferior vena cava. Note that coronary ligation was performed only in the donor heart.
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the presence of intestinal ischemia due to surgery, we
measured plasma endotoxin concentrations using an
endotoxin-specific chromogenic test (ES test; Seikagaku
Kogyo, Tokyo, Japan) on day 7, according to the method of
Obayashi et al. (10). To evaluate monocyte activity, the
plasma concentrations of monocyte chemoattractant protein
(MCP)-1 were determined with an enzyme-linked immu-
nosorbent assay kit for rat MCP-1 (Biosource, Camarillo,
California). Immunoenzymatic staining was performed with
a DAKO LSAB kit (DAKO, Carpinteria, California)
according to the manufacturer’s instructions. Antibody
against rat TNF-alpha (Cedarlae, Hornby, Ontario, Can-
ada) was used as the primary antibody.
Tissue and plasma concentrations of TNF-alpha were
determined as described previously (3). The tissue ANG II
content was determined by the method of Naik et al. (11).
Plasma ANG II concentrations were measured by radioim-
munoassay with florisil (12). Expression of TNF-alpha
messenger ribonucleic acid (mRNA) in the recipient heart
was measured by semiquantitative polymerase chain reac-
tion analysis (3). GAPDH was amplified using the primers
GAPDHF 5-GCCAAGTATGATGACATCAA-3 and
GAPDHR 5-CCATATTCATTGTCATACCA-3
(product size, 202 base pair). TNF-alpha was amplified
using the primers TNF-alphaF 5-ATGAGCACAGA-
AAGCATGATCC-3 and TNF-alphaR 5-GAAG-
ATGATCTGAGTGTG-3 (product size, 251 base pair).
For zonal quantification, the donor heart with MI was
divided into three pieces (infarct, border, and contralateral
zone), and in the case of donor hearts in the sham group and
recipient hearts, a whole heart was used because there were
no regional differences comparable to those measured in the
MI group.
Data are expressed as the mean value SD. The Student
t test was used to compare the differences between the two
groups. A p value 0.05 was considered statistically signif-
icant.
RESULTS
The operation yielded 48 cardiac transplantation–infarction
model rats from an initial total of 50 rats (96%). A total of
39 (98%) of 40 rats survived in the sham group. No graft
failure of the donor heart or gut ischemia occurred in either
group. Rats of the ligation group showed a significant
decrease in body weight and systolic blood pressure com-
pared with those of the sham group on day 7 (Table 1). In
contrast, body temperature and HR were significantly in-
creased on day 7 in the ligation group compared with the
sham group. There were no significant differences in these
parameters on day 21 between the sham and ligation groups.
Although the WBC counts and plasma MCP-1 levels were
significantly increased in the ligation group on day 7,
compared with the sham group, no statistical difference was
seen in the plasma endotoxin levels.
In the donor heart of the ligation group on day 7, the
heart weight, LVEDD, and LVESD were significantly
increased, whereas the peak systolic pressure, dP/dt, and
dP/dt were significantly decreased compared with those
values in the sham group (Table 2). There were no signif-
icant differences in the wall thickness of the noninfarcted
area, %FS, HR, or LV end-diastolic pressure (LVEDP) in
the donor heart between the two groups. On day 21, the
donor hearts in the ligation group demonstrated significant
LV scar formation. The heart weight, LVEDD, and
LVEDP were significantly higher, and %FS significantly
lower, in the ligation group than in the sham group. No
significant differences in the wall thickness of the nonin-
farcted area, LVESD, HR, peak systolic pressure, dP/dt,
or dP/dt were seen between the two groups.
In the recipient hearts of the ligation group on day 7,
LVEDD/body weight, HR, and LVEDP were significantly
increased, whereas %FS and dP/dt were significantly
decreased compared with those values in the sham group
(Table 3). No significant differences in the heart weight/
body weight, perivascular index, LVESD/body weight, wall
thickness, peak systolic pressure, or dP/dt of the recipient
heart were observed between the two groups on day 7. On
day 21, only the perivascular index was significantly in-
creased in the recipient heart of the ligation group compared
with the sham group. Plasma TNF-alpha concentrations in
the ligation group were significantly higher than those in
the sham group on days 2, 4, and 7 after surgery, with a peak
occurring on day 7. In contrast, no significant difference was
seen in plasma ANG II concentrations between the two
Table 1. Assessment of the Systemic Parameters of the Recipient After Surgery
Post-Surgical Period
7 Days 21 Days
Sham Ligation Sham Ligation
Body weight (g) 255  6 223  28* 343  14 341  23
Body temperature (°C) 36.7  0.3 37.8  0.2* 36.3  0.3 36.4  0.3
Heart rate (beats/min) 321  30 369  23* 308  41 318  44
Systolic blood pressure (mm Hg) 112  11 95  6* 124  15 112  19
WBC counts (/l) 7,733  945 12,800  2,394* 8,211  1,036 8,529  1,351
MCP-1 (pg/ml) 67  17 102  27* N/A N/A
Endotoxin (pg/ml) 6.1  3.7 5.7  2.3 N/A N/A
*p  0.05 vs. sham group. Data are expressed as the mean value  SD (n  6).
MCP  monocyte chemoattractant protein; N/A  not available; WBC  white blood cell.
175JACC Vol. 42, No. 1, 2003 Nakamura et al.
July 2, 2003:173–81 TNF-Alpha and Cardiac Remodeling
groups throughout the experiment (Fig. 2). There were no
relationships between plasma TNF-alpha and %MI (r 
0.45, p  0.17) or between ANG II and %MI (r  0.48, p
 0.17) on day 7.
We further analyzed the zonal production of TNF-alpha
and ANG II protein in the heart tissues of the sham and
ligation groups on day 7 (Fig. 3). Tissue TNF-alpha
concentrations in the recipient hearts of the ligation group
were significantly elevated compared with the recipient
hearts in the sham group. In contrast, in the donor heart,
the tissue ANG II content was significantly higher in the
infarct region than in other regions after surgery. There
were no differences in tissue TNF-alpha concentrations
among all regions in the donor hearts, and the tissue ANG
II content did not differ between the recipient hearts of the
two groups. In contrast, TNF-alpha mRNA in the recipient
heart was significantly lower in the ligation group than in
the sham group by 19% (Fig. 4).
Table 2. Morphometric, Echocardiographic, and Hemodynamic Assessment of the Donor Heart
Post-Surgical Period
7 Days 21 Days
Sham Ligation Sham Ligation
Morphometry
No. of experiments 5 5 6 7
Heart weight (g) 0.651  0.106 0.972  0.203* 0.549  0.071 1.033  0.303*
WT of noninfarct area (mm) 1.18  0.62 1.42  0.52 1.02  0.46 1.38  0.34
WT of infarct area (mm) N/A 0.99  0.46 N/A 0.61  0.24
%MI N/A N/A 0 49  6.6*
Echocardiography
No. of experiments 5 7 6 7
LVEDD (mm) 3.33  0.98 5.64  1.58* 3.19  0.69 5.01  2.08*
LVESD (mm) 2.91  0.88 4.93  1.34* 2.46  0.63 4.34  2.20
%FS 13.7  3.1 12.6  3.2 23.1  7.8 15.1  7.2*
Hemodynamics
No. of experiments 5 5 7 7
Heart rate (beats/min) 244  13 231  25 239  48 242  42
PSP (mm Hg) 78.1  18.4 50.4  19.6* 96.0  23.3 91.5  13.2
LVEDP (mm Hg) 5.8  1.5 7.0  5.2 5.9  2.9 23.5  21.9*
dP/dt (mm Hg/s) 2434  541 1204  462* 3166  748 2350  1203
dP/dt (mm Hg/s) 1,739  450 829  353* 2,334  645 1,648  711
*p  0.05 vs. sham group. Data are expressed as the mean  SD.
dP/dt rate of rise in left ventricular pressure; %FS percent fractional shortening; LVEDD left ventricular end-diastolic
dimension; LVEDP left ventricular end-diastolic pressure; LVESD left ventricular end-systolic dimension; %MI percent
myocardial infarction; N/A  not available; PSP  peak systolic pressure; WT  wall thickness.
Table 3. Morphometric, Echocardiographic, and Hemodynamic Assessment of the Recipient
Heart
Post-Surgical Period
7 Days 21 Days
Sham Ligation Sham Ligation
Morphometry
No. of experiments 5 5 5 7
HW/BW ( 103) 2.99  0.38 3.44  0.65 3.67  0.56 3.64  0.86
Perivascular index 0.23  0.06 0.31  0.14 0.19  0.11 0.70  0.17*
Echocardiography
No. of experiments 5 7 7 6
LVEDD/BW (mm/102g) 2.49  0.29 3.20  0.47* 2.12  0.24 2.01  0.30
LVESD/BW (mm/102g) 1.55  0.32 1.65  0.09 1.19  0.24 1.18  0.21
WT (mm) 1.33  0.10 1.19  0.11 1.25  0.13 1.25  0.19
%FS 47.8  5.5 41.3  1.6* 44.1  5.9 41.1  5.6
Hemodynamics
No. of experiments 5 5 7 7
Heart rate (beats/min) 322  34 378  18* 342  61 343  51
PSP (mm Hg) 123.0  10.2 112.0  16.3 124.4  16.8 103.5  29.8
LVEDP (mm Hg) 6.8  1.3 16.1  2.5* 6.2  2.8 5.7  0.9
dP/dt (mm Hg/s) 8,645  1,412 5,393  2,583* 8,356  2,321 6,532  2,791
dP/dt (mm Hg/s) 5,861  1,607 4,146  1,718 6,359  1,832 4,853  1,578
*p  0.05 vs. sham group. Data are expressed as the mean value  SD.
BW  body weight; HW  heart weight; other abbreviations as in Table 2.
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Immunohistochemical analysis showed that TNF-alpha
was positively stained in the cytoplasm of monocytes (yield-
ing a brown color with a pale blue background) taken from
the vessels of recipient hearts in the ligation group (Fig. 5).
Neither monocytes nor myocytes were positively stained
with TNF-alpha antibody in the sham group.
We further analyzed the effects of TNFR:Fc on the
function of recipient hearts of the ligation group. A single
injection of TNFR:Fc at the time of surgery significantly
decreased LVEDD and LVEDP levels, whereas dP/dt
increased compared with the TNFR:Fc nontreated ligation
group on day 7 (LVEDD: 3.20  0.47 vs. 2.11  0.17
mm/102 g [nontreated vs. treated group]; LVEDP: 16.1
2.5 vs. 3.0  2.7 mm Hg; dP/dt: 4,146  1,718 vs. 6,039
 530 mm Hg/s; n  6; p  0.05). There were no
significant differences in the morphometric, echocardio-
graphic, or hemodynamic assessment between the sham
group treated with TNFR:Fc and the untreated sham
group.
DISCUSSION
In our study, we found no significant difference in plasma
ANG II concentrations between the two groups at any time
during the experiment, whereas the tissue ANG II content
in the donor heart was significantly higher in the infarct
region than in other regions on day 7 after surgery. Left
ventricular remodeling and infarct healing after acute MI
appeared to be dynamic and time-dependent processes that
progressed in parallel to each other. Healing after acute MI
involves inflammatory cell infiltrations followed by fibro-
blast proliferation, collagen deposition, and remodeling in
the infarct zone. Structural LV remodeling after acute MI
involves early regional infarct expansion and progressive
global LV dilation (13). There is a general consensus that
acute MI is associated with an overexpression of the
renin-angiotensin system, which promotes structural LV
remodeling, with ANG II as the primary mediator. Inhibi-
tion of ANG II formation with angiotensin-converting
enzyme (ACE) inhibitors after acute MI has proven to be
effective overall as an anti-remodeling therapy (14). One of
the more interesting features in our study was the lack of a
role for ANG II. Most of the effects of ANG II are
autocrine/paracrine in nature (8), possibly because ligation
of the donor heart does not seem to perturb systemic
hemodynamics in a major way. Accordingly, systemic renin-
angiotensin system activation in the setting of acute coro-
nary ligation may be a reflection of a perturbation of
systemic hemodynamics, and the activation of pro-
inflammatory cytokines may be more of a response to
ischemic tissue injury and not necessarily related to systemic
hemodynamics.
It has been reported that early use of certain anti-
inflammatory agents promotes LV remodeling in patients
with MI (15). Clinical studies have demonstrated the
presence of activated circulating neutrophils, lymphocytes,
and monocytes, as well as increased levels of pro-
inflammatory cytokines such as TNF-alpha and C-reactive
protein (16). Studies of LV dysfunction have revealed that
baseline WBC counts are an independent predictor of
mortality, and WBC counts after acute MI have been
proposed as a means of risk stratification in patients with
LV dysfunction (17). After the early appearance of neutro-
phils subsequent to acute MI, monocytes migrate, interact-
ing with adhesion molecules, into the infarct zone, where
Figure 2. Time course of plasma tumor necrosis factor (TNF)-alpha and angiotensin II (ANG II) concentrations after surgery. Plasma ANG II
concentrations showed no difference between the two groups at any time point (lower panel), whereas plasma TNF-alpha concentrations were significantly
increased at 2, 4, and 7 days after surgery, compared with the sham group (upper panel). Data are expressed as the mean  SD (n  6). *p  0.05 vs.
sham group.
177JACC Vol. 42, No. 1, 2003 Nakamura et al.
July 2, 2003:173–81 TNF-Alpha and Cardiac Remodeling
they transform into macrophages, which are then activated.
The macrophages and monocytes secrete several factors,
such as macrophage colony–stimulating factor and MCP-1,
which lead to peripheral monocytosis and monocyte infil-
tration into the infarct zone, indicating that acute monocyte
recruitment may be involved in infarct healing (5,18).
Recently, Maekawa et al. (5) have found that the peak
monocyte count is an independent predictor of pump failure
and that the count correlates positively with LV end-
diastolic volume and negatively with the ejection fraction in
patients with acute MI reperfusion, suggesting a possible
role of monocytosis in the development of LV remodeling.
Although we did not measure monocyte counts in this
study, the WBC count and plasma MCP-1 concentrations,
but not the plasma endotoxin levels (a marker of exopyro-
gen), were significantly increased in the ligation group on
day 7, suggesting the activation of lymphocytes but not
neutrophils. As such, the monocyte/macrophage-rich
pathologic process may be involved in the development of
cardiac remodeling in our study model.
Using the conventional MI model, Irwin et al. (3)
demonstrated that TNF-alpha is not confined strictly to the
infarct or peri-infarct zone but is expressed by cardiac
myocytes within the myocardium contralateral to the in-
farct. They also suggested that expression of TNF-alpha
mRNA in the contralateral noninfarct zone persists until 35
days after surgery. In our study, tissue TNF-alpha in the
recipient heart, but not in the donor heart, and plasma
Figure 3. Tissue tumor necrosis factor-alpha (TNF)-alpha concentrations and angiotensin II (ANG II) content of the donor and recipient hearts on day
7. The tissue ANG II content was significantly increased only at the infarct region, whereas tissue TNF-alpha concentrations were significantly increased
only in the recipient heart of the ligation group. Data are expressed as the mean  SD (n  6). *p  0.05 vs. all of the other regions.
Figure 4. Semiquantitative polymerase chain reaction analysis of tumor
necrosis factor (TNF)-alpha messenger ribonucleic acid (mRNA) in the
recipient heart. Total tissue ribonucleic acid was separated and analyzed on
day 7. Data are expressed as the mean  SD (n  4). *p  0.05 vs. sham
group.
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TNF-alpha concentrations were significantly higher in the
ligation group than in the sham group on day 7, whereas
TNF-alpha mRNA in the recipient heart was significantly
lower in the ligation group than in the sham group.
Although we did not examine the expression of inflamma-
tory cytokines such as intercellular adhesion molecule-1 or
vascular cell adhesion molecule, TNF-alpha-expressing
monocytes were observed only in the lumen of the small
vessels in the recipient heart of the ligation group. We also
observed little migration of monocytes into the recipient
myocardium, suggesting that TNF-alpha in the recipient
heart may be derived from circulating monocytes. These
cytokines trigger the release and production of other cyto-
kines (19). Innate immunity could also provide a response to
ischemic stress, even in the same body, which is known as a
“systemic inflammatory response” (20). Activation of auto-
antibodies may be another candidate for the systemic
response to ischemic stress (21). Conversely, the expression
of TNF-alpha mRNA in the recipient heart of the ligation
group might be suppressed by elevated plasma TNF-alpha
levels produced by peripheral inflammatory cells such as
monocytes activated by myocardial ischemic stress, and
TNF-alpha was not positively stained in the recipient
myocardium of the ligation group, suggesting that recipient
heart tissue may not contribute to the TNF-alpha produc-
tion in this model. In contrast to the recipient heart, strong
TNF-alpha staining was revealed in the infarct and peri-
infarct zones of the ligated donor heart, which is in
agreement with the findings in the conventional MI model
(3; data not shown). Additionally, although the tissue
TNF-alpha concentration did not vary in different regions
of the donor heart, we cannot exclude the possibility that
TNF-alpha mRNA levels may vary from region to region.
Recent studies have focused on the role of TNF-alpha in
LV function and remodeling, as well as the development of
HF (22). In the present study, we showed that LV remod-
eling and dysfunction of recipients on day 7 can be pre-
vented by a single intravenous infusion of TNFR:Fc at the
time of surgery. These results suggest that TNFR:Fc may
bind to circulating plasma TNF-alpha derived from both
circulating monocytes and the donor heart in which isch-
emia is induced, rendering TNF-alpha less active (7). In
addition, elevated circulating TNF-alpha on day 7, which is
fairly late in the healing process in the conventional MI
model, may be due to differences in activation of the
neurohumoral and cytokine system and may play an impor-
tant role in LV dilation and dysfunction of the recipient
heart, which is remotely located from the remodeling donor
heart. On day 21, we observed no differences in plasma
TNF-alpha or ANG II, recipient cardiac function, or LV
dimension between the two groups, indicating that the
remote suppression effects of TNF-alpha on recipient car-
diac function might be transient. One exception was that
the perivascular index in the recipient heart was significantly
higher in the ligation group than in the sham group.
Macrophages secrete cytokines that stimulate fibroblast
proliferation and collagen deposition, which are important
during infarct healing (5). In our study, overproduction of
Figure 5. Photomicrographs of immunostained tumor necrosis factor (TNF)-alpha–positive cells in cross sections of the recipient heart in the ligation group
(a, b) and the sham group (c). (a, b) Many monocytes expressing TNF-alpha were observed only in the vessels. Arrows indicate TNF-alpha-positive cells.
(c) TNF-alpha-expressing cells were not observed in the recipient heart of the sham group. Scale bar  50 m.
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TNF-alpha, but not of ANG II, in the peripheral cells
around day 7 may have contributed to the peri-arterial
fibrosis seen in the recipient hearts on day 21. In this study,
we did not measure fibrosis and collagen in the infarct and
noninfarct zones and its correlation with remodeling, or the
effects of the TNF-alpha antagonist on fibrosis and colla-
gen, although collagen and the extracellular matrix are
important determinants of remodeling after MI (8,9).
Although clinical trials of patients with post-MI and
progressive chronic HF have indicated that ACE inhibitors
have a significant long-term benefit on morbidity and
mortality (23), clinical studies of Etanercept, a TNFR:Fc,
have failed to show additional benefits in patients with
chronic HF who have already been given an ACE inhibitor
(24). There are several explanations for the negative results
of anti-TNF-alpha therapies in clinical trails of HF. First,
the biologic agents used in the trials had intrinsic toxicity.
Second, TNF-alpha antagonists have adverse effects in the
setting of HF (21). Finally, all of the trials using the
TNF-alpha antagonist focused on the chronic phase, when
cardiac remodeling had already been established, but not on
the acute phase after MI. Our results with the TNF-alpha
antagonist are consistent with previous reports (7,21) and,
taken together with the results of a recent clinical study (24),
indicate that using the TNF-alpha antagonist to neutralize
activated cytokines during the acute phase of ischemic
stress/reperfusion injury might be a beneficial strategy for
the treatment of cardiac dysfunction and subsequent cardiac
remodeling after acute MI.
Recently, Depre et al. (25) introduced an unloaded heart
model in which the donor heart was isolated from the
recipient heart and showed a parallel-circuit circulation
distinct from the series-circuit circulation of the recipient.
In their study, when donor hearts of sham rats were
compared with recipient hearts of sham rats, the donor
cardiac function was less than the recipient cardiac function,
which maintains the systemic blood supply. In our experi-
ment, we performed an additional coronary ligation and
obtained MI in the donor heart. Infarct wall thinning and
expansion in the absence of an increase in noninfarcted wall
thickness are consistent with remodeling in the donor heart
with MI. This phenomenon may have caused some differ-
ences in the results between our current model and the
conventional MI model (1,3). The most important differ-
ence between these two models is not the loading condition
but the ischemia in the donor heart. In our model, the donor
heart is located parallel to the recipient circulation, so that
the donor heart continues to beat independent of the
recipient hemodynamics, with a higher survival rate. More-
over, our model allows one to examine the difference
between the local and remote effects of cytokines and
neurohormones—as activated by cardiac ischemia—on car-
diac dysfunction and remodeling after acute MI. Note that
practitioners should be cautions about extrapolating the
results from our model and applying them directly to
humans.
Conclusions. We have developed a novel heterotopic car-
diac transplantation–coronary ligation model capable of
inducing MI in the absence of downstream hemodynamic
effects and allowing differential quantification of indexes of
cardiac remodeling in vivo, such as the local and remote
effects of ANG II and TNF-alpha on cardiac remodeling.
We believe that our model could be used in trials of cytokine
modulation of post-MI remodeling and will provide new
insights into LV remodeling and dysfunction.
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